Commodore Capital significantly reduced its investment in clinical-stage biotech company Nuvalent during the fourth quarter of 2025, divesting 850,000 shares valued at approximately $83.81 million. The transaction brought the fund's stake down from 9.26% to 3.68% of its total assets, marking a substantial repositioning of its biotech exposure.
The divestment occurred against a backdrop of strong market performance for the company's shares, which have gained 29% over the past twelve months. Nuvalent continues to maintain a solid financial position with cash runway extending into 2029, providing the company with sufficient liquidity to advance its clinical pipeline without near-term funding pressures.
The biotech firm has several upcoming catalysts that could influence investor sentiment. Most notably, the company expects a Prescription Drug User Fee Act (PDUFA) decision for its lead candidate zidesamtinib in September, which represents a key milestone for the organization's development strategy and potential commercial prospects.